Low-grade non-muscle-invasive bladder cancer progresses rarely but recurs in 50%–70% of cases, and transurethral resection carries perioperative risks and inpatient burden. In this single-center study, all ablations were performed in the outpatient clinic under local anesthesia with a diode laser, routine cold-cup biopsies, and systematic NBI; patients with positive cytology, high-grade disease, carcinoma in situ, or muscle-invasive cancer were excluded. Over a mean follow-up of 24.2 ± 14.7 months, 44 of 71 patients (62%) recurred. Recurrence was associated with younger age (median 52.5 vs. 65 years,
p < 0.001) and more than three original tumors (40.9% vs. 11.1%,
p = 0.01), and multivariable analysis identified age (OR = 0.79), comorbidities, follow-up duration, and number of ablated tumors (OR = 2.50) as independent predictors.
No patient progressed to muscle-invasive disease, and there were no cases of bladder perforation, significant hematuria, urinary retention, or hospital admission. The authors conclude that NBI-guided diode laser ablation is safe and well tolerated, offering effective local control without general anesthesia or hospitalization, while noting that the retrospective single-center design, small sample size, and lack of a TURBT comparator require prospective validation.
The work titled “Narrow band imaging‐guided diode laser ablation in recurrent low‐grade non‐muscle‐invasive bladder cancer” was published in
UroPrecision (published on May 7, 2026).
doi:
10.1002/uro2.70069